Skip to main
MNMD

MNMD Stock Forecast & Price Target

MNMD Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Mind Medicine Inc. is focused on developing innovative treatments for brain health disorders through its advanced product candidates, particularly MM120 for generalized anxiety disorder and MM402 for autism spectrum disorder. The Phase 2b trials for MM120 showed compelling efficacy with significant improvements in the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Hamilton Anxiety Rating Scale (HAM-A), indicating its potential superiority over the current standard of care. With strong Phase 3 studies planned for completion in 2026 and positive preclinical data for MM402, Mind Medicine is well-positioned to capitalize on the rising adoption of psychedelic treatments, suggesting substantial upside potential in its stock valuation.

Bears say

Mind Medicine Inc. faces significant challenges related to its reliance on patent protection for its product candidates, with potential disputes or failures in patent issuance posing risks to the company's market success and overall valuation. Clinical and regulatory hurdles may hinder the approval process for its key products, including MM120 and MM402, which could adversely affect future collaborations and revenue streams. Additionally, the company's conservative clinical data assumptions suggest that its pipeline may be less competitive compared to alternate treatment options, raising concerns about its ability to capture market share in the brain health disorder sector.

MNMD has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mind Medicine MindMed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mind Medicine MindMed (MNMD) Forecast

Analysts have given MNMD a Strong Buy based on their latest research and market trends.

According to 9 analysts, MNMD has a Strong Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mind Medicine MindMed (MNMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.